Abstract
Cigarette smoking is the leading cause of preventable morbidity and mortality. Genetic variation contributes to initiation, regular smoking, nicotine dependence, and cessation. We present a Fagerström Test for Nicotine Dependence (FTND)-based genome-wide association study in 58,000 European or African ancestry smokers. We observe five genome-wide significant loci, including previously unreported loci MAGI2/GNAI1 (rs2714700) and TENM2 (rs1862416), and extend loci reported for other smoking traits to nicotine dependence. Using the heaviness of smoking index from UK Biobank (N = 33,791), rs2714700 is consistently associated; rs1862416 is not associated, likely reflecting nicotine dependence features not captured by the heaviness of smoking index. Both variants influence nearby gene expression (rs2714700/MAGI2-AS3 in hippocampus; rs1862416/TENM2 in lung), and expression of genes spanning nicotine dependence-associated variants is enriched in cerebellum. Nicotine dependence (SNP-based heritability = 8.6%) is genetically correlated with 18 other smoking traits (rg = 0.40–1.09) and co-morbidities. Our results highlight nicotine dependence-specific loci, emphasizing the FTND as a composite phenotype that expands genetic knowledge of smoking.
Original language | English |
---|---|
Article number | 5562 |
Pages (from-to) | 1-13 |
Number of pages | 13 |
Journal | Nature Communications |
Volume | 11 |
Issue number | 1 |
Early online date | 3 Nov 2020 |
DOIs | |
Publication status | Published - 3 Nov 2020 |
Funding
This work was supported by the National Institute on Drug Abuse grant numbers R01 DA042090 (PI: DBH) and R01 DA036583 (PI: LJB) and by National Cancer Institute grant number U19 CA203654 (LJB; PI: Amos). The authors thank deCODE Genetics / Amgen and its investigators (Gunnar W. Reginsson, Thorgeir E. Thorgeirsson, and Kari Stefansson) for their data contributions, which were supported in part by NIDA R01 DA017932 (PI: Kari Stefansson). Acknowledgments for all other ND studies, which were contributed by the authors and/or made publicly available, are included in Supplementary Note 1. UK Biobank Resource data were obtained under Application Number 24603.
Funders | Funder number |
---|---|
National Institute on Drug Abuse | R01 DA017932, R01 DA042090, R01 DA036583, R01DA042195 |
National Cancer Institute | U19 CA203654 |
Amgen |